Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk today announced clinical results from a 26-week phase 3a treat-to-target study comparing DegludecPlus, a soluble combination of ultra-long-acting insulin degludec and insulin aspart, to insulin glargine in Japanese people with type 2 diabetes inadequately controlled on oral antidiabetic drugs. This is the 18th announced phase 3a study in the Degludec and DegludecPlus clinical trial development programme.
http://www.pipelinereview.com/index...-in-Japanese-people-with-type-2-diabetes.html
http://www.pipelinereview.com/index...-in-Japanese-people-with-type-2-diabetes.html